ImmunoPrecise Antibodies (CVE:IPA – Get Rating) released its quarterly earnings results on Wednesday. The company reported C($0.38) EPS for the quarter, reports. The firm had revenue of C$4.69 million for the quarter.
ImmunoPrecise Antibodies Stock Performance
IPA stock traded up C$0.37 during mid-day trading on Friday, reaching C$6.87. 14,074 shares of the stock traded hands, compared to its average volume of 20,186. The firm has a market capitalization of C$170.63 million and a PE ratio of -7.72. The business has a 50-day moving average of C$6.32 and a two-hundred day moving average of C$6.19. ImmunoPrecise Antibodies has a 52 week low of C$4.52 and a 52 week high of C$8.99. The company has a quick ratio of 3.60, a current ratio of 4.05 and a debt-to-equity ratio of 3.38.
Get
ImmunoPrecise Antibodies alerts:
About ImmunoPrecise Antibodies
(Get Rating)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes.
Featured Stories
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
ImmunoPrecise Antibodies (CVE:IPA – Get Rating) released its quarterly earnings results on Wednesday. The company reported C($0.38) EPS for the quarter, reports. The firm had revenue of C$4.69 million for the quarter.
免疫精抗体公司(CVE:IPA-GET Rating)周三发布了季度收益报告。据报道,该公司公布本季度每股收益为0.38加元。该公司本季度的收入为469万加元。
ImmunoPrecise Antibodies Stock Performance
IPA stock traded up C$0.37 during mid-day trading on Friday, reaching C$6.87. 14,074 shares of the stock traded hands, compared to its average volume of 20,186. The firm has a market capitalization of C$170.63 million and a PE ratio of -7.72. The business has a 50-day moving average of C$6.32 and a two-hundred day moving average of C$6.19. ImmunoPrecise Antibodies has a 52 week low of C$4.52 and a 52 week high of C$8.99. The company has a quick ratio of 3.60, a current ratio of 4.05 and a debt-to-equity ratio of 3.38.
IPA股价在周五午盘交易中上涨0.37加元,达到6.87加元。该股有14,074股易手,而其平均成交量为20,186股。该公司市值为1.7063亿加元,市盈率为-7.72。该业务的50日移动均线切入位在6.32加元,200日移动均线切入位在6.19加元。免疫精抗体的52周低点为4.52加元,52周高位为8.99加元。该公司的速动比率为3.60,流动比率为4.05,债务权益比为3.38。
Get
ImmunoPrecise Antibodies
alerts:
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes.
免疫精抗体有限公司及其子公司在美国、加拿大、欧洲、澳大利亚和国际上从事抗体生产和提供相关服务。该公司提供一系列抗体、酶、酶活性分析、关节炎动物产品、蛋白质、去亚胺蛋白、有机生长因子和杂交瘤产品用于研究目的。
Featured Stories
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- 股市:红海中的三座强国
- 第四季度值得考虑的3家银行
- MarketBeat:回顾一周9/12-9/16
- 没有人告诉这三只股票这是下跌的一周
- 有什么办法可以治愈Teladoc股票的问题吗?
Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到关于免疫精准抗体的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收最新新闻和分析师对免疫精准抗体和相关公司的评级的每日摘要。